Growth Metrics

KalVista Pharmaceuticals (KALV) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for KalVista Pharmaceuticals (KALV) over the last 8 years, with Q2 2025 value amounting to $4.7 million.

  • KalVista Pharmaceuticals' Cash from Financing Activities fell 9689.6% to $4.7 million in Q2 2025 from the same period last year, while for Apr 2025 it was $158.1 million, marking a year-over-year increase of 486.88%. This contributed to the annual value of $159.7 million for FY2025, which is 598.02% up from last year.
  • KalVista Pharmaceuticals' Cash from Financing Activities amounted to $4.7 million in Q2 2025, which was down 9689.6% from $295000.0 recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Cash from Financing Activities registered a high of $150.1 million during Q2 2024, and its lowest value of $128000.0 during Q4 2023.
  • In the last 3 years, KalVista Pharmaceuticals' Cash from Financing Activities had a median value of $295000.0 in 2024 and averaged $22.7 million.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Cash from Financing Activities soared by 137058.82% in 2024, and later crashed by 9689.6% in 2025.
  • Quarter analysis of 3 years shows KalVista Pharmaceuticals' Cash from Financing Activities stood at $128000.0 in 2023, then surged by 130.47% to $295000.0 in 2024, then soared by 1479.32% to $4.7 million in 2025.
  • Its Cash from Financing Activities stands at $4.7 million for Q2 2025, versus $295000.0 for Q4 2024 and $3.0 million for Q3 2024.